Overview
Jimyung Kim practices practicing medicine in Daejeon, Republic of Korea.
Their clinical expertise encompasses Acute Promyelocytic Leukemia, Philadelphia-Negative Chronic Myeloid Leukemia, Myeloproliferative Neoplasms (MPN), and Acute Myeloid Leukemia (AML).
They are actively involved in clinical research, co-authoring 21 peer reviewed articles.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Jimyung Kim
Is Jimyung Kim a top-rated expert for Acute Promyelocytic Leukemia?
MediFind is an objective health platform that identifies experts based on real-world data. Jimyung Kim is classified as an Experienced expert for Acute Promyelocytic Leukemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Jimyung Kim participate in research or clinical trials?
Yes. Jimyung Kim has published 21 articles and abstracts on conditions like Acute Promyelocytic Leukemia. You can view a list of Jimyung Kim's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Acute Myeloid Leukemia (AML)
- Acute Promyelocytic Leukemia
- LeukemiaKim isExperienced. Learn about Leukemia.
- Myeloproliferative Neoplasms (MPN)
- Philadelphia-Negative Chronic Myeloid Leukemia